Academician Xu Binghe: breast cancer has entered the era of "chronic disease" and needs to strengthen the "two guarantees" management
2023-04-18
As a common and high incidence malignant tumor in the world, breast cancer can be called the "number one killer" of women. With the continuous improvement of cancer prevention and treatment in China, what progress has been made in the prevention and treatment of breast cancer? During the National Cancer Prevention and Control Week this year, Professor Xu Binghe, an academician of the CAE Member and director of the National New Drug (Anti tumor) Clinical Research Center, received an exclusive interview with Xinhuanet. He said that China's cancer prevention and control work has entered a new stage of development. The overall five-year survival rate of malignant tumors has increased from 30.9% ten years ago to 40.5%, an increase of nearly 10 percentage points, and is still rising. Compared with other tumors, the comprehensive prevention and treatment level of breast cancer has made "faster progress". The survival period of patients continues to extend. The prevention and control of breast cancer has entered the era of "chronic disease", and its prevention and control strategy has also turned to all-round and life-cycle "two guarantees" health management, so that patients can not only live longer, but also live better. The comprehensive prevention and treatment level of breast cancer has been greatly improved. Xu Binghe said that the comprehensive prevention and treatment level of breast cancer in China has been greatly improved, which is mainly reflected in the improvement of early diagnosis and early treatment rate, the improvement of comprehensive treatment level, the emergence of new therapies and drugs, and the improvement of treatment philosophy. "In the past, less than 20% of breast cancer patients in China were in the first stage, while foreign patients accounted for 40% - 50%. With the continuous progress of breast cancer screening, the proportion of early stage patients in China is gradually increasing." Xu Binghe said, followed by progress in comprehensive treatment. In the 1970s and 1980s, the five-year survival rate of breast cancer in China was only 50% - 60%. Now, through surgery, radiotherapy and comprehensive medical treatment, the five-year survival rate of breast cancer nationwide has reached 83%. In some large hospitals, such as the Cancer Hospital of the Chinese Academy of Medical Sciences, the 5-year survival rate exceeds 93%. The continuous development and updating of new technologies, new therapies and new drugs have also contributed to the improvement of the diagnosis and treatment of breast cancer. "The improvement of treatment concept is also very important." Xu Binghe said for example, endocrine therapy used to use single drug therapy. After the advent of targeted drugs, endocrine therapy combined with CDK4/6 inhibitors and other targeted drugs became a new standard, and endocrine drugs combined with targeted drug therapy significantly extended the survival period of patients with advanced breast cancer. In the past, the survival period of advanced breast cancer patients with positive receptor hormone was only 2-3 years, but now some clinical research results confirm that the 5-year survival rate can reach 50%. " As an advocate and practitioner of individualized diagnosis and treatment of breast cancer in China, Academician Xu Binghe has devoted 40 years to the field of oncology medicine and clinical and transformation research of breast cancer, and has been "overcoming difficulties" in improving the status quo of breast cancer prevention and treatment, including HER2 positive breast cancer, hormone receptor positive breast cancer, and the so-called "most dangerous" triple negative breast cancer. "Three negative breast cancer accounts for about 15% of all breast cancer patients. In the past, treatment methods were very limited, and it was generally considered that treatment was difficult. Now, through many studies, it is believed that three negative breast cancer is a large class of diseases composed of many small subtypes. Different treatments can be developed for different subtypes," said Xu Binghe, "Therefore, patients with triple negative breast cancer should not be particularly afraid. If it is early detection, early diagnosis and early treatment,
Edit：Guanguan Responsible editor：Niexiaoqian
Source：XinhuaNet
Special statement: if the pictures and texts reproduced or quoted on this site infringe your legitimate rights and interests, please contact this site, and this site will correct and delete them in time. For copyright issues and website cooperation, please contact through outlook new era email：lwxsd@liaowanghn.com
Recommended Reading Change it 
Home
